Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic diseases by targeting the biology of human aging. Company announcements highlight progress in its lead NLRP3 inhibitor program, preclinical obesity programs, and collaborations with larger pharmaceutical partners.
A key focus of recent news is BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BioAge has reported interim data from an ongoing Phase 1 single and multiple ascending dose trial, including information on safety, pharmacokinetics, and pharmacodynamic effects on inflammatory biomarkers such as IL-1β, hsCRP, IL-6, and fibrinogen in healthy volunteers and obese participants with elevated inflammation.
News updates also cover BioAge’s broader pipeline and strategy. The company issues releases on the advancement of long-acting injectable and oral small-molecule APJ agonists for obesity, including a nanobody APJ agonist under an exclusive option agreement and a portfolio of orally active APJ agonists. In addition, BioAge communicates developments in its discovery platform based on human longevity data and its multi-year collaborations with Novartis and Lilly ExploR&D on metabolic aging targets.
Investors following BIOA news can expect coverage of clinical milestones for BGE-102, preclinical and regulatory progress for APJ agonist programs, financial results, and participation in healthcare and biotechnology conferences. This page aggregates those updates so readers can review BioAge’s clinical data disclosures, partnership announcements, and strategic commentary in one place.
BioAge (Nasdaq: BIOA) on January 20, 2026 announced a proposed underwritten public offering of up to $75.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million. All shares will be offered by the company and the offering is subject to market and other conditions with no assurance of completion or final terms. Goldman Sachs, Piper Sandler and Citigroup are joint book‑running managers. Net proceeds, together with existing cash and marketable securities, are intended to fund research, clinical and process development including BGE-102, NLRP3 and APJ programs, working capital, capex and reduction of indebtedness. The offering will be filed on Form S-3.
BioAge (Nasdaq: BIOA) is expanding development of oral NLRP3 inhibitor BGE-102 into ophthalmology, initiating a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) in mid-2026 with results expected mid-2027. BGE-102 showed favorable tolerability in Phase 1 and robust reductions in inflammatory biomarkers (hsCRP, IL-6, IL-1β). Preclinical data report near-complete protection from retinal vascular leakage and up to 90% microvascular preservation. The DME POC will test intraocular IL-6 percent change and include BCVA and CST endpoints.
BioAge (Nasdaq: BIOA) reported interim Phase 1 MAD cohort results for BGE-102, an oral, brain-penetrant NLRP3 inhibitor for patients with obesity and elevated inflammation. In the 120 mg once-daily cohort (n=14), BGE-102 achieved a 86% median hsCRP reduction at Day 14 and 93% of participants reached hsCRP <2 mg/L; 71% reached ≤1 mg/L. BGE-102 also produced a 44% median IL-6 reduction, 30% fibrinogen reduction, and 93% IL-1β suppression in an ex vivo assay. Safety was favorable with no dose-limiting toxicities. Company plans full Phase 1 readout and Phase 2a initiation in 1H 2026.
BioArctic (Nasdaq: B) partner Eisai announced that Leqembi (lecanemab) has been included in China’s new Commercial Insurance Innovative Drug List, effective January 1, 2026. The list enables commercial insurers to negotiate coverage products for listed innovative medicines, aiming to narrow the gap with the National Reimbursement Drug List.
Eisai launched Leqembi in China in June 2024 and estimates 17 million people had MCI or mild dementia due to Alzheimer’s in China in 2024. Leqembi was originally developed by BioArctic and is commercialized in China by Eisai; BioArctic retains Nordic commercialization rights and is preparing joint commercialization with Eisai in that region.
BioAge (Nasdaq: BIOA) reported positive interim Phase 1 data for BGE-102, a brain-penetrant oral NLRP3 inhibitor, on Dec 4, 2025. In SAD (10–120 mg) and initial MAD (60, 120 mg) cohorts, BGE-102 was well tolerated and showed dose-proportional pharmacokinetics supporting once-daily dosing.
Key results: IL-1β suppression 90–98% at Day 14 (60–120 mg), and CSF concentrations at ≥60 mg exceeded target IC90 after 14 days, indicating high brain penetration. MAD plasma levels at ≥60 mg exceeded IC90 for 24 hours.
The company expanded MAD cohorts to enroll obese participants with elevated hsCRP; data are anticipated in 1H 2026. Phase 2a is planned to start in 1H 2026 with ~100 patients and a 2H26 readout.
BioArctic partner Eisai (NYSE:B) presented CTAD 2025 data showing continued lecanemab (Leqembi) treatment may delay Alzheimer’s progression by up to 8.3 years in a low‑amyloid subgroup who started treatment early. Analysis used Clarity AD OLE and ADNI natural‑history data to estimate 10‑year time savings by CDR‑SB, with overall delays of 2.5–3.5 years vs untreated and larger gains in low‑amyloid patients.
Separately, a subcutaneous autoinjector (SC‑AI) approved for maintenance in the US (Aug 2025) showed bioequivalent exposure to IV dosing (exposure ratio 104%, 90% CI 99.1%–109%), low systemic infusion reactions, ADA 1.4%, and predicted ARIA‑E rates of 12.4% (30.9% in ApoE4 homozygotes). sBLA for initiation completed Nov 2025; Japan SC submission Nov 2025.
BioAge Labs (NASDAQ: BIOA) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2-4, 2025. Company leaders Kristen Fortney, PhD, CEO, and Dov Goldstein, MD, CFO, will participate in a fireside chat on December 4, 2025 from 1:30–1:55 PM ET and will hold one-on-one meetings.
A live webcast will be available with registration, and replays will be archived in the company investor section at https://ir.bioagelabs.com/ for 30 days after the presentations.
BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.
Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.
BioArctic (NASDAQ: B) partner Eisai received MHRA approval in the United Kingdom for Leqembi (lecanemab) as a once-every-four-weeks IV maintenance treatment for early Alzheimer’s disease on November 14, 2025.
After an initial 18-month induction of 10 mg/kg every two weeks, patients may be transitioned to 10 mg/kg every four weeks or remain on the two-week schedule. Leqembi previously received a UK approval in August 2024 for treatment of MCI and mild dementia due to Alzheimer’s in ApoE ε4 heterozygotes and non-carriers. BioArctic and Eisai are preparing joint commercialization in the Nordic region, where BioArctic holds commercialization rights.
BioAge Labs (NASDAQ: BIOA) will present at the Jefferies Global Healthcare Conference in London on November 17–20, 2025. The company said CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, will join a fireside chat on Monday, November 17 from 7:30–7:55 AM ET (12:30–1:00 PM GMT) and will hold one-on-one meetings.
Investors can watch a live webcast by registering via the company link and access replays in the investor section at https://ir.bioagelabs.com/; replays will be archived for 30 days after the presentations.
FAQ
What is the current stock price of BioAge Labs (BIOA)?
What is the market cap of BioAge Labs (BIOA)?
